- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04765059
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COMPEL)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients With EGFRm, Locally Advanced or Metastatic NSCLC Who Have Progressed Extracranially Following First-Line Osimertinib Therapy (COMPEL)
Study Overview
Status
Conditions
Detailed Description
This is a Phase III, randomized, double-blind, placebo-controlled study of platinum plus pemetrexed chemotherapy plus osimertinib versus platinum plus pemetrexed chemotherapy plus placebo in patients with epidermal growth factor receptor mutation-positive (EGFRm), locally advanced or metastatic NSCLC with or wihout stable brain metastases who responded to first-line osimertinib therapy (complete response [CR] or partial response [PR]) or stable disease (SD) for ≥ 6 months during first-line osimertinib treatment, and subsequently experienced radiological, extracranial disease progression. Approximately 204 patients were to be randomized in a 1:1 ratio to treatment with platinum plus pemetrexed chemotherapy plus osimertinib (Treatment Arm A) or platinum plus pemetrexed chemotherapy plus placebo (Treatment Arm B). However, the number of patients has been reduced to approximately 80 patients due to treatment landscape changes which outpaced study recruitment. Patients will be stratified based on the presence of brain metastases (stable brain metastases based on central nervous system (CNS) Response Evaluation Criteria in Solid Tumors, Version 1.1 [RECIST 1.1] assessments versus no brain metastases).
The 2 randomized treatment regimens are as follows:
- Treatment Arm A: Osimertinib 80 mg once daily (QD) with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin (area under the concentration-time curve [AUC] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles
- Treatment Arm B: Placebo QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin (AUC5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by placebo QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: AstraZeneca Clinical Study Information Center
- Phone Number: 1-877-240-9479
- Email: information.center@astrazeneca.com
Study Locations
-
-
-
Beijing, China, 100142
- Research Site
-
Beijing, China, 100005
- Research Site
-
Ganzhou, China, 341000
- Research Site
-
Guangzhou, China, 510080
- Research Site
-
Hohhot, China, 010017
- Research Site
-
Jinan, China, 250013
- Research Site
-
Linyi, China, 276000
- Research Site
-
Shenyang, China, 110001
- Research Site
-
Tianjin, China, 300060
- Research Site
-
Wuxi, China, 214023
- Research Site
-
Xiangfan, China, 441021
- Research Site
-
Zhengzhou City, China, 450008
- Research Site
-
-
-
-
-
Berlin, Germany, 12351
- Research Site
-
Hannover, Germany, 30625
- Research Site
-
Köln, Germany, 51109
- Research Site
-
Köln, Germany, 50937
- Research Site
-
München, Germany, D-80336
- Research Site
-
Ulm, Germany, 89081
- Research Site
-
-
-
-
-
Beer Sheva, Israel, 84101
- Research Site
-
Jerusalem, Israel, 9112001
- Research Site
-
Jerusalem, Israel, 9103102
- Research Site
-
Kfar Saba, Israel, 4428164
- Research Site
-
Tel Aviv, Israel, 6423906
- Research Site
-
Tel Hashomer, Israel, 52621
- Research Site
-
-
-
-
-
Firenze, Italy, 50134
- Research Site
-
Meldola, Italy, 47014
- Research Site
-
Messina, Italy, 98158
- Research Site
-
Napoli, Italy, 80131
- Research Site
-
Padova, Italy, 35128
- Research Site
-
Roma, Italy, 00168
- Research Site
-
Terni, Italy, 05100
- Research Site
-
Verona, Italy, 37124
- Research Site
-
-
-
-
-
Alicante, Spain, 03010
- Research Site
-
Barcelona, Spain, 08907
- Research Site
-
Cordoba, Spain, 14004
- Research Site
-
Cáceres, Spain, 10003
- Research Site
-
León, Spain, 24071
- Research Site
-
Madrid, Spain, 28040
- Research Site
-
Murcia, Spain, 30008
- Research Site
-
Málaga, Spain, 29010
- Research Site
-
Oviedo, Spain, 33011
- Research Site
-
Palma de Mallorca, Spain, 07010
- Research Site
-
Sevilla, Spain, 41013
- Research Site
-
Valencia, Spain, 46010
- Research Site
-
-
-
-
Maryland
-
Silver Spring, Maryland, United States, 20910
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol.
- Pathologically confirmed non-squamous NSCLC.
- Locally advanced (clinical stage IIIB or IIIC) or metastatic NSCLC (clinical stage IVA or IVB) or recurrent NSCLC, not amenable to curative surgery or radiotherapy.
- Evidence of radiological extracranial disease progression following (Investigator-assessed) response or SD for ≥ 6 months during first-line osimertinib treatment, but who have not received further, subsequent treatment.
- Tumor known to harbor 1 of the 2 or both common epidermal growth factor receptor (EGFR) mutations known to be associated with EGFR tyrosine kinase inhibitor (TKI) sensitivity (Ex19del or L858R), either alone or in combination with other EGFR mutations, which may include T790M.
- World Health Organization performance status of 0 to 1 at screening with no clinically significant deterioration in the previous 2 weeks.
- Life expectancy >12 weeks at Day 1.
- At least 1 lesion, not previously irradiated, that can be accurately measured.
- Females must be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential, or must have evidence of non-childbearing potential by fulfilling criteria at screening.
- Male patients must be willing to use barrier contraception
Exclusion Criteria:
- Clinical or radiological evidence of CNS progression on first-line osimertinib.
- Past medical history of interstitial lung disease (ILD)/pneumonitis, drug-induced ILD/pneumonitis, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD/pneumonitis.
- Any evidence of severe or uncontrolled systemic diseases.
Any of the following cardiac criteria:
i) Mean resting QTc >470 msec ii) Any clinically important abnormalities in rhythm, conduction, or morphology of resting electrocardiogram iii) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events
- Any concurrent and/or other active malignancy that has required treatment within 2 years of first dose of investigational product (IP).
- Any unresolved toxicities from prior therapy.
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.
- More than 4 weeks elapsed since last dose of osimertinib by date of randomization.
- Unable to tolerate osimertinib 80 mg first-line therapy.
- Prior treatment with any systemic anti-cancer therapy.
- Major surgery within 4 weeks of the first dose of IP.
- Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of IP.
- Current use of medications or herbal supplements known to be strong inducers of cytochrome P450 (CYP) 3A4.
- Participation in another clinical study with an IP other than first-line osimertinib during the 4 weeks prior to Day 1.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm A
All randomized patients will receive osimertinib 80 mg QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin ([AUC] 5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by osimertinib 80 mg QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles
|
Randomized patients will receive oral dose of osimertinib with intravenous (IV) pemetrexed plus either IV cisplatin or IV carboplatin
|
Placebo Comparator: Treatment Arm B
All randomized patients will receive placebo QD with pemetrexed (500 mg/m^2) (with pre-treatment) plus either cisplatin (75 mg/m^2) or carboplatin (AUC5), both administered on Day 1 of 21-day cycles for 4 cycles, followed by placebo QD plus pemetrexed maintenance (500 mg/m^2) on Day 1 of 21-day cycles
|
Randomized patients will receive oral dose of placebo matching osimertinib with IV pemetrexed plus either IV cisplatin or IV carboplatin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival(PFS):time from randomization until progression(intra- or extracranial whichever occurs first)per RECIST 1.1(for extracranial)and CNS RECIST 1.1(for intracranial progression)as assessed by Investigator or death due to any cause
Time Frame: At Screening,every 6 weeks for the first 13 cycles (each cycle is 21 days),then every 12 weeks, relative to randomization,and upto intracranial or extracranial disease progression or end of survival follow-up,whichever comes first (approximately 3 years)
|
To compare the efficacy of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo based on PFS
|
At Screening,every 6 weeks for the first 13 cycles (each cycle is 21 days),then every 12 weeks, relative to randomization,and upto intracranial or extracranial disease progression or end of survival follow-up,whichever comes first (approximately 3 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intracranial PFS is defined as time from randomization until intracranial progression per CNS RECIST 1.1 as assessed by the Investigator at local site or death due to any cause
Time Frame: At Screening,every 6 weeks for the first 13 cycles (each cycle is 21 days), then every 12 weeks, relative to randomization, and upto intracranial disease progression or end of survival follow-up, whichever comes first (approximately 3 years)
|
To compare the efficacy of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo based on intracranial PFS in patients with baseline brain metastases and patients without baseline brain metastases
|
At Screening,every 6 weeks for the first 13 cycles (each cycle is 21 days), then every 12 weeks, relative to randomization, and upto intracranial disease progression or end of survival follow-up, whichever comes first (approximately 3 years)
|
Extracranial PFS is defined as time from randomization until extracranial progression per RECIST 1.1 as assessed by the Investigator at local site or death due to any cause
Time Frame: At Screening,every 6 weeks for the first 13 cycles (each cycle is 21 days), then every 12 weeks, relative to randomization, and upto extracranial disease progression or end of survival follow-up, whichever comes first (approximately 3 years)
|
To compare the efficacy of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo based on extracranial PFS
|
At Screening,every 6 weeks for the first 13 cycles (each cycle is 21 days), then every 12 weeks, relative to randomization, and upto extracranial disease progression or end of survival follow-up, whichever comes first (approximately 3 years)
|
OS: the length of time from randomization until the date of death due to any cause
Time Frame: From randomization through post progression survival follow-up (up to approximately 3 years)
|
To compare the efficacy of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo based on OS
|
From randomization through post progression survival follow-up (up to approximately 3 years)
|
Number of patients with serious and non-serious adverse events
Time Frame: From screening through post progression survival follow-up (at least once every 12 weeks relative to randomization)
|
To assess the safety and tolerability of chemotherapy plus osimertinib treatment relative to chemotherapy plus placebo in patients with locally advanced or metastatic EGFRm NSCLC whose disease has progressed extracranially on first-line osimertinib treatment.
|
From screening through post progression survival follow-up (at least once every 12 weeks relative to randomization)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Folic Acid Antagonists
- Carboplatin
- Cisplatin
- Osimertinib
- Pemetrexed
Other Study ID Numbers
- D5162C00042
- 2019-003969-18 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)WithdrawnStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
-
AstraZenecaActive, not recruitingNon-Small Cell Lung CancerUnited States, Canada, Thailand, Vietnam, France, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, Russian Federation, China, Taiwan, United Kingdom, Czechia, Chile, Australia, Argentina, Slovakia, South Africa
-
AstraZenecaNot yet recruitingLung CancerThailand, Vietnam, Korea, Republic of, India, China, Taiwan, United States, Israel, Spain, Turkey
-
BeiGeneCompletedNon-Small Cell Lung CancerChina
-
Beijing Cancer Prevention & Treatment SocietyCancer Institute and Hospital, Chinese Academy of Medical SciencesRecruitingNon Small Cell Lung CancerChina
-
Hutchison Medipharma LimitedRecruitingNon-small Cell Lung CancerChina
-
Innovent Biologics (Suzhou) Co. Ltd.Not yet recruitingNon-squamous Non-small-cell Lung CancerChina
-
AstraZenecaRecruitingNon-Small Cell Lung CancerChina, United States, Chile, Vietnam, Thailand, Brazil, Bulgaria, Canada, Germany, India, Japan, Korea, Republic of, Poland, Russian Federation, Singapore, Turkey, Austria, Israel, Spain, Taiwan, Mexico, France, Italy, Peru, Switzerland, United...
-
West China HospitalJiangsu HengRui Medicine Co., Ltd.UnknownApatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLCLung Cancer | Non Small Cell Lung Cancer | Apatinib | Combination ChemotherapyChina
-
ImmunityBio, Inc.Active, not recruitingNon Small Cell Lung CancerUnited States
-
Sun Yat-sen UniversityRecruitingNon-Small Cell Lung CancerChina